Effects of the 5‐HT 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain

Effects of the 5‐HT 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the... 1 The ability of the selective 5‐HT3 receptor antagonist GR38032F to reduce raised mesolimbic dopaminergic activity was studied in behavioural experiments in the rat and marmoset. 2 GR38032F injected into the nucleus accumbens (0.01–1 ng) or peripherally (0.01–1 mg kg−1 i.p.) inhibited the locomotor hyperactivity caused by the acute intra‐accumbens injection of amphetamine (10 μg) in the rat. Similar treatments with sulpiride and fluphenazine also inhibited the amphetamine‐induced hyperactivity. 3 The peripheral administration of GR38032F (0.001–0.1 mg kg−1 i.p., b.d.) during a 13 day period of dopamine infusion (25 μg 24 h−1) into the nucleus accumbens of the rat reduced the dopamine‐induced hyperactivity response to control (vehicle infused) levels. Locomotor activity remained at control levels after discontinuing the dopamine/GR38032F treatment regimen. 4 The hyperactivity caused by the infusion of dopamine into the rat nucleus accumbens was also inhibited by fluphenazine (0.01‐0.05 mg kg−1 i.p., b.d.), but locomotor activity was suppressed to levels below control values and a rebound hyperactivity occurred after discontinuation of the dopamine/fluphenazine treatment regimen. 5 The discontinuation of a concomitant 13 day intra‐accumbens infusion of dopamine with haloperidol, 0.01 mg kg−1 i.p. t.d.s., caused a rebound hyperactivity. This hyperactivity was suppressed by GR38032F (0.001‐0.1 mg kg−1 i.p.). 6 The unilateral infusion of dopamine (25 μg 24 h−1, 13 days) into the left amygdala of rats having right hemispheric dominance (as measured in a turn preference test) caused locomotor hyperactivity. Intraperitoneal administration of GR38032F (0.1–100 μg kg−1) or fluphenazine (0.025‐0.1 mg kg−1), and the intra‐amygdaloid injection of GR38032F (0.1–100 ng) or fluphenazine (25–500 pg), either into the infused or non‐infused side, inhibited the dopamine‐induced locomotor hyperactivity. 7 Marmosets receiving bilaterial infusions of dopamine (25 μg 24 h−1 for 13 days) into the nucleus accumbens also exhibited increased locomotor activity. GR38032F (0.1‐1.0 μg kg−1 t.d.s.), reduced the hyperactivity to control levels with no rebound hyperactivity following the discontinuation of the dopamine/GR38032F treatment regimen. Fluphenazine (0.01–2.5 mg kg−1 i.p., t.d.s.) also inhibited the hyperactivity, but locomotor activity was reduced to values below control levels and a rebound hyperactivity followed the discontinuation of the dopamine/fluphenazine treatment. 8 It is concluded that the 5‐HT3 receptor antagonist GR38032F, and the neuroleptic agents fluphenazine, sulpiride and haloperidol, can reduce raised mesolimbic dopaminergic activity in the rat and marmoset. GR38032F is distinguished from the dopamine receptor antagonists by, firstly, its ability to return the hyperactivity response to control values, without excessive suppression of locomotion even on enhanced dosage regimes and, secondly, by the lack of rebound hyperactivity following abrupt discontinuation of its treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Effects of the 5‐HT 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain

Loading next page...
 
/lp/wiley/effects-of-the-5-ht-3-receptor-antagonist-gr38032f-on-raised-qbluzD6vcG
Publisher
Wiley
Copyright
1987 British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
DOI
10.1111/j.1476-5381.1987.tb11394.x
Publisher site
See Article on Publisher Site

Abstract

1 The ability of the selective 5‐HT3 receptor antagonist GR38032F to reduce raised mesolimbic dopaminergic activity was studied in behavioural experiments in the rat and marmoset. 2 GR38032F injected into the nucleus accumbens (0.01–1 ng) or peripherally (0.01–1 mg kg−1 i.p.) inhibited the locomotor hyperactivity caused by the acute intra‐accumbens injection of amphetamine (10 μg) in the rat. Similar treatments with sulpiride and fluphenazine also inhibited the amphetamine‐induced hyperactivity. 3 The peripheral administration of GR38032F (0.001–0.1 mg kg−1 i.p., b.d.) during a 13 day period of dopamine infusion (25 μg 24 h−1) into the nucleus accumbens of the rat reduced the dopamine‐induced hyperactivity response to control (vehicle infused) levels. Locomotor activity remained at control levels after discontinuing the dopamine/GR38032F treatment regimen. 4 The hyperactivity caused by the infusion of dopamine into the rat nucleus accumbens was also inhibited by fluphenazine (0.01‐0.05 mg kg−1 i.p., b.d.), but locomotor activity was suppressed to levels below control values and a rebound hyperactivity occurred after discontinuation of the dopamine/fluphenazine treatment regimen. 5 The discontinuation of a concomitant 13 day intra‐accumbens infusion of dopamine with haloperidol, 0.01 mg kg−1 i.p. t.d.s., caused a rebound hyperactivity. This hyperactivity was suppressed by GR38032F (0.001‐0.1 mg kg−1 i.p.). 6 The unilateral infusion of dopamine (25 μg 24 h−1, 13 days) into the left amygdala of rats having right hemispheric dominance (as measured in a turn preference test) caused locomotor hyperactivity. Intraperitoneal administration of GR38032F (0.1–100 μg kg−1) or fluphenazine (0.025‐0.1 mg kg−1), and the intra‐amygdaloid injection of GR38032F (0.1–100 ng) or fluphenazine (25–500 pg), either into the infused or non‐infused side, inhibited the dopamine‐induced locomotor hyperactivity. 7 Marmosets receiving bilaterial infusions of dopamine (25 μg 24 h−1 for 13 days) into the nucleus accumbens also exhibited increased locomotor activity. GR38032F (0.1‐1.0 μg kg−1 t.d.s.), reduced the hyperactivity to control levels with no rebound hyperactivity following the discontinuation of the dopamine/GR38032F treatment regimen. Fluphenazine (0.01–2.5 mg kg−1 i.p., t.d.s.) also inhibited the hyperactivity, but locomotor activity was reduced to values below control levels and a rebound hyperactivity followed the discontinuation of the dopamine/fluphenazine treatment. 8 It is concluded that the 5‐HT3 receptor antagonist GR38032F, and the neuroleptic agents fluphenazine, sulpiride and haloperidol, can reduce raised mesolimbic dopaminergic activity in the rat and marmoset. GR38032F is distinguished from the dopamine receptor antagonists by, firstly, its ability to return the hyperactivity response to control values, without excessive suppression of locomotion even on enhanced dosage regimes and, secondly, by the lack of rebound hyperactivity following abrupt discontinuation of its treatment.

Journal

British Journal of PharmacologyWiley

Published: Dec 1, 1987

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off